作者
Anjali S Advani, Anna B Moseley, Kristen M O'Dwyer, Brent L Wood, Jae H Park, Matthew J Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L Atallah, Aaron T Gerds, Susan M O'Brien, Jane L Liesveld, Megan Othus, Mark R Litzow, Richard M Stone, Elad Sharon, Cecilia CS Yeung, Jerald P Radich, Harry P Erba
发表日期
2023/11/28
期刊
Blood
卷号
142
页码范围
1499
出版商
Content Repository Only!
简介
Tyrosine kinase inhibitors (TKIs) have improved the outcomes of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Many older patients (pts) are not good candidates for intensive chemotherapy and are treated with TKIs plus corticosteroids or low-intensity chemotherapy. Although the remission rates with this approach have been high, the median disease-free survival (DFS) has been short. Therefore, novel treatment strategies are needed. This trial evaluated the feasibility of combining the TKI dasatinib with prednisone and blinatumomab in older pts with Ph+ ALL. Here we present updated results (median follow-up, 4.3 years).
Methods: This trial was activated through the NCTN in January 2015 and closed to accrual in April 2021. Pt eligibility included: age ≥ 65 years; Ph+ or Ph-like ALL (with dasatinib-sensitive fusions or mutations); newly diagnosed or relapsed/ refractory …
学术搜索中的文章
AS Advani, AB Moseley, KM O'Dwyer, BL Wood… - Blood, 2023